Posted innews Oncology Otorhinolaryngology
Lower, More Frequent Cisplatin Dosing Substantially Reduces Hearing Loss in Head and Neck Cancer Without Compromising Short‑Term Survival
A multicenter retrospective cohort shows weekly low‑dose cisplatin markedly lowers ototoxicity compared with standard high‑dose every‑3‑week cisplatin in CRT for head and neck squamous cell carcinoma, with similar two‑year survival.
